Cabinet Office to Organize Society 5.0 Expo to Showcase Japan’s Advanced Technologies and Achievements
14.7.2021 09:00:00 EEST | Business Wire | Press release
The Government of Japan’s Cabinet Office announced that it will organize the Society 5.0 Expo jointly with the Japan Agency for Marine-Earth Science and Technology (JAMSTEC) from 15 July at TOKYO SKYTREE TOWN® in Tokyo, Japan. This is expected to be Japan’s first major expo to focus on Society 5.0. The expo will also be viewable online with multilingual explanations for the global audience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713006253/en/
[From upper-left] SHINKAI 6500, HAYABUSA2, Wearable Cyborg, Active scope camera for rescue [From lower-left] Ultra-thin and flexible tough polymer, Rescue robot, Small synthetic-aperture radar satellite (SAR), Communication robot, Flying car, Level-3 autonomous vehicle (Photo: Business Wire)
The expo will showcase the Society 5.0 concept proposed by the Japanese government as a highly desirable future society. The concept envisions the creation of a human-centered society in which all industries and other areas of society adopt AI, IoT, robots, big data and other innovative technologies to overcome critical challenges. The Cabinet Office’s 6th Science, Technology and Innovation Basic Plan covering fiscal 2021 to 2025 sets forth the direction of science, technology and innovation policies to secure sustainability, resilience and the well-being of diverse individuals.
The expo will present achievements being realized through national projects focused on increasing innovation in society, including the cross-ministerial strategic innovation promotion program (SIP) and the ImPACT program for stimulating high-risk, high-impact R&D. Japan’s scientific and technological aspirations will be conveyed through numerous displays of advanced technologies.
Specifically, some 50 leading Japanese companies, universities and organizations will exhibit approximately 200 products and research achievements that are expected to contribute not only to Society 5.0 but also the UN’s Sustainable Development Goals. The exhibits will cover fields such as mobility, healthcare and caregiving, manufacturing, agriculture, food, disaster prevention and energy, including:
- Asteroid-explorer Hayabusa2’s returned capsule
- Full-scale model of SHINKAI 6500 submersible piloted to 6,500 meters undersea
- SkyDrive flying car
- Honda Legend Level-3 autonomous vehicle with high-definition 3D mapping
- Model of small synthetic-aperture radar satellite system for on-demand launches and instant observation
- HAL wearable cyborg that transmits brain signals to human muscles for assistance with physical functions
- Disaster-prevention systems for heavy rain and tornado forecasting and ICT-based information sharing
- Smart agriculture technology, such as an automated water supply and drainage system
International viewers will be welcome to enjoy the many exhibits viewable online via mobile devices and PCs, supported with explanations available in a number of languages. The organizers will be pleased to present the virtual exhibition as an opportunity for the global community to learn more about Japan’s forward-looking Society 5.0 concept.
Exhibits will be grouped under the follow themes:
Stage 1 Prologue
The opening theme will present a full-scale model of the SHINKAI 6500 research submersible and a Dagik Earth three-dimensional digital globe, etc. Satellite-based technologies that are being deployed on a practical working basis in various sectors also will be introduced.
Stage 2 Science Frontiers—Space and Ocean
Exhibits of Japan's world-class space-exploration technology will include models of the International Space Station, the "Kibo" Japanese Experiment Module, a full-scale rocket engine, and the Hayabusa2 return capsule.
Exhibits of Japan’s ocean exploration and environmental-simulation technology will include autonomous underwater vehicles for exploring hydrothermal vents and ocean-floor resources and advanced solutions for ocean research.
Stage 3 5.0 Society of the Future
Science and technologies developed through Japan’s SIP and ImPACT programs and how they will help to enhance life in five areas: 1) 100-year lifespans, 2) Mobility and social interaction, 3) Infrastructure for more resilient and safer life, 4) Human- and earth-friendly lifestyles and 5) Advanced manufacturing. Exhibits will include automated solutions such as robots, vehicles and drones, disaster-prevention systems such as AI for infrastructure inspections, robotic industrial borescopes, next-generation energy and resources such as ammonia fuel and ocean-floor minerals, and advanced materials such as synthetic spider silk and strong but flexible ultra-thin polymers.
Stage 4 Trajectory toward Society 5.0
The evolution of human civilization will be presented through videos and other visuals portraying Society 1.0 (hunting & gathering), 2.0 (agriculture), 3.0 (industry) and 4.0 (information) as well as 5.0 (at TOKYO SKYTREE® Tembo Galleria, the closest point to space in Tokyo).
Stage 5 Society 5.0 Theater
Films from the Japan Aerospace Exploration Agency (JAXA) and JAMSTEC will be aired. Also, researchers and experts will give presentations about science, oceans, disaster prevention and ICT for advanced technology and innovation.
Please download official images from here.
Outline of Society 5.0 Expo
|
Organizers |
Cabinet Office and Japan Agency for Marine-Earth Science and Technology (JAMSTEC) |
|
|
Venue |
Exhibition areas within TOKYO SKYTREE TOWN |
|
|
|
- Pavilion at TOKYO SKYTREE TOWN Sky Arena (4F) |
|
|
|
- TOKYO SKYTREE TOWN Solamachi Square (1F) |
|
|
|
- TOKYO SKYTREE Group Floor (1F) |
|
|
|
- TOKYO SKYTREE Tembo Galleria |
|
|
|
- TOKYO SKYTREE TOWN campus of Chiba Institute of Technology |
|
|
|
|
|
|
Dates |
15 July to 5 September 2021 |
|
|
|
- Physical exhibitions by enterprises (15 July to 19 July) |
|
|
|
- Physical exhibitions by other organizations (15 July to 28 July) |
|
|
|
- Sub-exhibition by posters and videos (15 July to 5 September) |
|
|
|
- Virtual exhibition (17 July to 5 September) with multi-language explanations
|
|
|
Admission |
Free (Admission to sub-exhibition by ticket, sold at TOKYO SKYTREE Tembo Galleria) |
|
|
Exhibitors and partners |
Please refer to the list on the official website |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713006253/en/
Contact information
Society 5.0 media inquiries
Weber Shandwick
Mayuko Harada (+81-90-9006-4968)
Rina Uesugi (+81-90-2280-0041)
E-mail: society5.0expo@webershandwick.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom